Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Key Facts on Billing Drug Wastage

From the College  |  January 24, 2023

In 2017, the Centers for Medicare & Medicaid Services (CMS) released claims-processing guidance clarifying the use of the JW modifier and how to bill Medicare for discarded drugs and biologics. This billing guideline is still in effect for all providers. The intent of the wasted/discarded drugs and biologics coding policy is to minimize waste and/or abuse.

When a physician, other provider, hospital or supplier must discard the remainder of a single-dose vial (SDV) or other single-use package after administering a dose/quantity of the drug or biologic agent to a  patient, Medicare will reimburse for the discarded amount, as well as the dose administered, up to the amount indicated on the vial or package label. Per Medicare guidelines the amount administered must be reported on one line and the amount of drug not administered (i.e., wasted) on a separate line with the modifier JW. The JW must be appended to the associated Healthcare Common Procedure Coding System (HCPCS) code.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The JW modifier is applicable only to the amount of the drug discarded or wasted, and not to the amount administered. Further, the amount wasted and identified by the JW modifier must be at least equal to one billing unit. For example, if the HCPCS code is reportable in 10 mg increments and 7 mg of a 10 mg SDV is administered, report the entire billing unit without a separate line for the amount wasted. If a HCPCS code is reportable in 10 mg increments and 70 mg from a 100 mg SDV is administered, the provider may report seven bill units as administered, and on a separate line report three units with the JW modifier appended to the HCPCS code to indicate the drug amount discarded.

To avoid any overpayment for drugs billed, always round up the amount administered to the next billing unit and round down the amount of drug discarded. For example, if an HCPCS code is reportable in 10 mg increments and the provider administers 77 mg from a 100 mg SDV, report eight units as administered and, on a separate line, report two units with the JW modifier appended to the HCPCS code to indicate the amount discarded.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As always, Medicare expects the administration of drugs to be scheduled and performed in an efficient manner, minimizing the amount of drug wastage.

The JW modifier is not permitted to identify discarded amounts from a multi-dose vial (MDV).

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Billing/Coding Tagged with:Billing & Coding

Related Articles

    New HCPCS Modifiers Replace -59 on January 1, 2015

    December 1, 2014

    Referred to as -X modifiers, they are designed to define specific subsets of -59 modifier

    Rheumatology Coding Corner Answer: Billing Infusion Procedure with JW Modifier

    April 20, 2017

    Take the challenge. CPT: 99214-25, 96413, 96375, 96361-59, J1745 x 4 J1745 JW* x 36, J1200 x1 ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEICD-10: M45.09, T50.995A, R06.02, E66.3, Z68.2 Rationale Modifier 25 is appropriate to use because it indicates the patient received a significant, separately identifiable E/M service on the same day as the infliximab infusion. This…

    Coding Corner Answer: March

    March 1, 2015

    Coding for chemotherapy infusion with a drug reaction

    Coding Corner Answer: A Quiz on Modifiers

    February 18, 2019

    Take the challenge. 1. A—Modifier -25 is defined as a significant, separately identifiable evaluation and management (E/M) service by the same physician or other qualified healthcare professional on the same day of the procedure or other service. It is to be placed on the E/M visit only because it attests to the payer there is…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences